Mazdutide
Category
Weight Loss (GLP-1/Glucagon)
Frequency
Once weekly injection
Research
Phase 3 Clinical Trials
What is Mazdutide
Mazdutide (IBI362) is a dual GLP-1 receptor and glucagon receptor agonist developed by Innovent Biologics in China. It shares the dual-agonist approach of retatrutide but without the GIP component — instead pairing GLP-1 with glucagon agonism, which drives thermogenesis and direct fat oxidation. Browse all weight loss peptide options to compare.
In Phase 3 clinical trials conducted primarily in Chinese and Asian populations, Mazdutide demonstrated approximately 18% body weight reduction over 36 weeks — positioning it between tirzepatide (22.5%) and semaglutide (15%) in terms of efficacy. Given that clinical trial populations were Asian, results may be particularly relevant to Philippines users.
Mazdutide also shows promise beyond weight loss — trials have demonstrated improvements in NAFLD (fatty liver disease), with significant reductions in liver fat content. This makes it particularly interesting for users with metabolic liver conditions.
How it works
GLP-1 Agonism: Activates GLP-1 receptors to suppress appetite, enhance insulin secretion, and slow gastric emptying — the same core mechanism as Semaglutide and the GLP-1 component of Tirzepatide.
Glucagon Agonism: Activates glucagon receptors which directly increase metabolic rate (thermogenesis), stimulate fat oxidation particularly in the liver, and enhance energy expenditure. This is the key differentiator from pure GLP-1 drugs.
Hepatic Fat Reduction: The glucagon component has particular efficacy in reducing liver fat (hepatic triglycerides), making Mazdutide uniquely effective for NAFLD/MAFLD alongside its weight loss properties.
Reported benefits
- 01~18% average body weight reduction in Phase 3 trials
- 02Significant reduction in liver fat — useful for NAFLD
- 03Improved insulin sensitivity and HbA1c reduction
- 04Favorable Asian population trial data (directly relevant)
- 05Weekly dosing for convenience
- 06Thermogenic effect from glucagon agonism
- 07Emerging availability as research peptide in the Philippines
Dosing protocol
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Starting | 3mg | Once weekly | Weeks 1–4 |
| Titration | 4.5–6mg | Once weekly | Weeks 5–12 |
| Maintenance | 6mg | Once weekly | Ongoing |
Always start at the lowest effective dose and titrate up gradually.
Side effects
Common
- Nausea (most common during titration)
- Decreased appetite
- Diarrhea
- Vomiting (resolves with slower titration)
- Injection site reactions
Rare
- ·Elevated liver enzymes (monitor if pre-existing liver disease)
- ·Hypoglycemia risk with concurrent diabetes medications
- ·Gallbladder issues (associated with rapid weight loss)
- ·Pancreatitis (rare, discontinue if severe abdominal pain)
Who should not use Mazdutide
What to expect
Week 1–4
Starting dose phase. Appetite reduction begins. Nausea may occur but is typically manageable.
Week 5–8
Appetite markedly reduced at titration dose. Weight loss accelerates, often 1–1.5kg per week with dietary awareness.
Month 3–6
Consistent fat loss continues. The glucagon component produces noticeable thermogenic benefit — users often report feeling warmer and more energetic.
FAQ
Is Mazdutide available in the Philippines?
Mazdutide is less widely available than retatrutide or tirzepatide but is emerging in the research peptide market. Check the community-verified supplier list for current Philippines availability and verify purity with the COA verification guide.
How does Mazdutide compare to Tirzepatide?
Tirzepatide combines GLP-1 and GIP, while Mazdutide combines GLP-1 and Glucagon. Tirzepatide generally produces slightly more weight loss (22.5% vs 18%), but Mazdutide may have superior effects on liver fat. Both are weekly injections at similar price points.
Is Mazdutide FDA approved?
No — Mazdutide is developed by a Chinese company and has primarily been trialed in China. It is not FDA approved but is available as a research peptide. It shares the same receptor mechanisms as approved drugs (Ozempic, Mounjaro) so the safety profile is relatively well understood.
Where to get Mazdutide in the Philippines
See our community-verified supplier list with COA verification and cold-chain shipping to the Philippines.
Risk · Disclosure · Editorial Status
This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician — ideally one with peptide-specific clinical experience — before starting any compound, adjusting a dose, or discontinuing therapy.
In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.
Editorial Status
Independent · Non-clinical
Affiliation
Not a clinic · Not a pharmacy
Last Updated
—
↗ Related peptides